Parkinson’s Disease Therapeutics Market Insights: Size, Share, Growth Analysis & Forecast (2024-2029)
The market report provided a comprehensive analysis segmented by Drug Class (Levodopa Combination, Dopamine Agonists, Others); by Route of Administration (Oral, Transdermal, Others); by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy); by Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa).
Outlook
- The Parkinson’s disease therapeutics market is estimated to be at USD 6,225.75 Mn in 2024 and is anticipated to reach USD 8,644.01 Mn in 2029.
- The Parkinson’s disease therapeutics market is registering a CAGR of 6.78% during the forecast period of 2024-2029.
- The global prevalence of Parkinson’s disease (PD) has been steadily rising, particularly in aging populations. Therapeutics are increasingly addressing non-motor symptoms of Parkinson’s, such as cognitive impairment, sleep disturbances, and depression.
Request a free sample.
Ecosystem
- The participants in the global Parkinson’s disease therapeutics industry lead the market through ongoing research, innovation, and product launches aimed at improving symptom management.
- These companies primarily focus on exploring the synergistic effects of combining different drugs to enhance therapeutic outcomes, along with mergers and acquisitions to maintain a competitive edge on the market.
- Several important entities in the Parkinson’s disease therapeutics market include Novartis Pharmaceuticals Corp.; Orion Pharma Pty Ltd.; Daiichi Sankyo Co., Ltd.; UCB Biopharma SRL; Boehringer Ingelheim Group; and others.
Ask for customization.
Findings
| Attributes | Values |
|---|---|
| Historical Period | 2018-2022 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Market Size (2024) | USD 6,225.75 Mn |
| Market Size (2029) | USD 8,644.01 Mn |
| Growth Rate | 6.78% CAGR from 2024 to 2029 |
| Key Segments | Drug Class (Levodopa Combination, Dopamine Agonists, Others (MAO-B Inhibitors, COMT Inhibitors)); Route of Administration (Oral, Transdermal, Others (Subcutaneous, Intestinal Infusion)); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy); Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa) |
| Key Vendors | Novartis Pharmaceuticals Corp.; Orion Pharma Pty Ltd.; Daiichi Sankyo Co. Ltd.; UCB Biopharma SRL; Boehringer Ingelheim Group |
| Key Countries | The US; Canada; Mexico; Brazil; Argentina; China; India; Japan; South Korea; The UK; Germany; Italy; France; Spain; Turkey; UAE; Saudi Arabia; Egypt; South Africa |
| Largest Market | North America |
Get a free quote.
Trends
- Gene Therapy: Gene therapy is becoming a transformative force in Parkinson’s treatment. It aims to address the underlying causes rather than just managing symptoms. In 2023, Voyager Therapeutics made significant strides with its gene therapy targeting the GBA1 gene, offering potential long-term benefits by addressing genetic contributors to PD.
- Research in Neuroprotective Strategies: Research in neuroprotection is increasing, with scientists seeking therapies that can slow disease progression. In 2023, the Michael J. Fox Foundation announced a USD 10 million grant to support research into neuroprotective treatments that could halt or reverse damage to dopamine-producing neurons.
- Personalized Medicine Initiatives: Personalized medicine is becoming more prominent in Parkinson’s treatment as genetic testing and patient-specific drug responses gain focus. In 2023, 23andMe expanded its genetic testing offerings for Parkinson’s predisposition, influencing how therapies are tailored to individual patients.
Speak to analyst.
Catalysts
- Adoption of Wearable Devices: The integration of wearable devices to track symptoms and drug efficacy is gaining momentum. In 2023, Medtronic partnered with Global Kinetics to incorporate its wearable devices in clinical trials, enhancing real-time data collection for PD management.
- Prevalence of Parkinson’s Disease: The rising prevalence of Parkinson’s disease is a key driver of market growth. According to the World Health Organization (WHO), over 8.5 million people were living with Parkinson’s disease globally in 2023, with the numbers expected to increase as the global population ages.
- Early Detection: Improved diagnostic tools are helping to detect Parkinson’s disease earlier, which increases the demand for therapeutic intervention earlier in the disease’s progression. In 2023, the Parkinson’s Foundation launched a global campaign to improve early detection, leading to more timely interventions and treatment initiations.
Inquire before buying.
Restraints
- Side Effects of Long-Term Medication: Long-term use of Parkinson’s disease medications like levodopa can lead to side effects, including dyskinesia and motor fluctuations, presenting challenges in long-term patient management. In 2023, Johns Hopkins Medicine published findings that highlight the need for more effective strategies to mitigate these side effects over extended treatment periods.
- Limited Efficacy of Current Therapies: Over time, the effectiveness of current treatments, like levodopa, can diminish. This makes it challenging to manage symptoms effectively, particularly in the later stages of the disease. In 2023, the European Parkinson’s Disease Association noted that existing therapies remain primarily palliative, urging for more research into disease-modifying treatments.
- Lack of Standardized Biomarkers: The absence of standardized biomarkers for diagnosing and tracking Parkinson’s disease progression presents a challenge for developing effective therapies. In 2023, researchers at the Karolinska Institute emphasized the need for consistent biomarker use in clinical trials to improve therapeutic outcomes.
Personalize this research.
Hotspot
Explore purchase options.
Table of Contents
| 1. Introduction 1.1. Research Methodology 1.2. Scope of the Study 2. Market Overview / Executive Summary 2.1. Global Parkinson’s Disease Therapeutics Market (2018 – 2022) 2.2. Global Parkinson’s Disease Therapeutics Market (2023 – 2029) 3. Market Segmentation 3.1. Global Parkinson’s Disease Therapeutics Market by Drug Class 3.1.1. Levodopa Combination 3.1.2. Dopamine Agonists 3.1.3. Others 3.2. Global Parkinson’s Disease Therapeutics Market by Route of Administration 3.2.1. Oral 3.2.2. Transdermal 3.2.3. Others 3.3. Global Parkinson’s Disease Therapeutics Market by Distribution Channel 3.3.1. Hospital Pharmacy 3.3.2. Retail Pharmacy 3.3.3. Online Pharmacy 4. Regional Segmentation 4.1. North America 4.1.1. The US 4.1.2. Canada 4.1.3. Mexico 4.2. South America 4.2.1. Brazil 4.2.2. Argentina 4.2.3. Colombia 4.2.4. Chile 4.2.5. Rest of South America 4.3. Asia Pacific 4.3.1. China 4.3.2. India 4.3.3. Japan 4.3.4. South Korea 4.3.5. Rest of Asia Pacific 4.4. Europe 4.4.1. The UK 4.4.2. Germany 4.4.3. Italy 4.4.4. France 4.4.5. Spain 4.4.6. Rest of Europe 4.5. The Middle East 4.5.1. Turkey 4.5.2. UAE 4.5.3. Saudi Arabia 4.5.4. Rest of the Middle East 4.6. Africa 4.6.1. Egypt 4.6.2. South Africa 4.6.3. Rest of Africa 5. Value Chain Analysis of the Global Parkinson’s Disease Therapeutics Market 6. Porter Five Forces Analysis 6.1. Threats of New Entrants 6.2. Threats of Substitutes 6.3. Bargaining Power of Buyers 6.4. Bargaining Power of Suppliers 6.5. Competition in the Industry 7. Trends, Drivers and Challenges Analysis 7.1. Market Trends 7.1.1. Market Trend 1 7.1.2. Market Trend 2 7.1.3. Market Trend 3 7.2. Market Drivers 7.2.1. Market Driver 1 7.2.2. Market Driver 2 7.2.3. Market Driver 3 7.3. Market Challenges 7.3.1. Market Challenge 1 7.3.2. Market Challenge 2 7.3.3. Market Challenge 3 8. Opportunities Analysis 8.1. Market Opportunity 1 8.2. Market Opportunity 2 8.3. Market Opportunity 3 9. Competitive Landscape 9.1. Novartis Pharmaceuticals Corp. 9.2. Orion Pharma Pty Ltd. 9.3. Daiichi Sankyo Co., Ltd. 9.4. UCB Biopharma SRL 9.5. Boehringer Ingelheim Group 9.6. Company 6 9.7. Company 7 9.8. Company 8 9.9. Company 9 9.10. Company 10 |
Know the research methodology.
Parkinson’s Disease Therapeutics Market – FAQs
1. What is the current size of the Parkinson’s disease therapeutics market?
Ans. In 2024, the Parkinson’s disease therapeutics market size is $6,225.75 Mn.
2. Who are the major vendors in the Parkinson’s disease therapeutics market?
Ans. The major vendors in the Parkinson’s disease therapeutics market are Novartis Pharmaceuticals Corp.; Orion Pharma Pty Ltd.; Daiichi Sankyo Co., Ltd.; UCB Biopharma SRL; Boehringer Ingelheim Group.
3. Which segments are covered under the Parkinson’s disease therapeutics market segments analysis?
Ans. The Parkinson’s disease therapeutics market report offers in-depth insights into Drug Class, Route of Administration, Distribution Channel, and Geography.